Jeff Reeves’s Strength in Numbers: 5 biotech buyout candidates you should look at right now

Biotech stocks are often reliant on broader investing trends. When Wall Street is “risk on” and willing to deal with some of the inherent volatility, it’s not uncommon for stocks in this sector to make big moves. But when the bloom is off the rose, biotech can often underperform in an equally big way.

In the last year or so, as the markets rallied nicely, biotech has decidedly returned to favor. The SPDR Biotech ETF XBI, -1.54% has surged more than 50% in the last 12 months and the iShares Biotechnology ETF IBB, -0.78% is up roughly 30% versus about 25% gains for the S&P 500 SPX, -0.06% in the same period.

>>> Original Source <<<